DOWNLOAD
Access this content:
If you are an existing investor, log in first to your Metrobank Wealth Manager account.
If you wish to start your wealth journey with us, click the “How To Sign Up” button.
Fundamental View
AS OF 03 Dec 2025AZN enjoys one of the strongest growth profiles in our coverage, reflecting a portfolio of innovative medicines, particularly in Oncology. The addition of Alexion supports AZN’s growth prospects, bringing strong assets in immune-mediated rare diseases.
AZN also enjoys relatively strong diversification, with core sales coming from multiple therapeutic areas and with depth across its Oncology and Biopharma platforms.
AZN’s capital allocation priorities include investment in the business, the pursuit of value-enhancing bolt-on M&A, and support for the dividend.
Business Description
AS OF 03 Dec 2025- AstraZeneca is a UK-based pharmaceutical company that researches, develops, and manufactures drugs with a focus in (i) Oncology, (ii) Cardiovascular, Renal and Metabolism (CVRM), (iii) Respiratory and Immunology, (iv) Rare Disease, and (v) Vaccines and Immune.
- AstraZeneca operates in five primary segments: Oncology, CVRM (cardiovascular, renal, and metabolism), Respiratory and Immunology, Rare Diseases, and V&I (Vaccines and Immune). AstraZeneca reported FY24 revenues of $54.1 bn, with ~41% from Oncology, ~23% from CVRM, ~15% from Respiratory and Immunology, and ~16% from Rare Diseases.
- In recent years, AstraZeneca has acquired Alexion for $39 bn, CinCor for $1.8 bn, Fusion for $2 bn, among other smaller transactions.
Risk & Catalysts
AS OF 03 Dec 2025Given that AZN’s leverage has been largely restored to pre-Alexion levels, we expect limited deliberate improvement from here. However, we expect future shareholder rewards and business development to be managed somewhat conservatively.
AstraZeneca has shown discipline with respect to leverage and capital allocation in recent years. While AstraZeneca pays a relatively aggressive dividend (~31% of LTM FCF), the company has historically been very conservative with share repurchases and has even used share issuance to fund certain acquisitions.
AZN recently lost a patent-infringement lawsuit against Samsung Biologics regarding a biosimilar version of Soliris.
Key Metric
AS OF 03 Dec 2025| $ mn | Y20 | Y21 | Y22 | Y23 | Y24 | LTM 3Q25 |
|---|---|---|---|---|---|---|
| Revenue | 26,617 | 37,417 | 44,351 | 45,811 | 54,073 | 58,127 |
| Gross Profit | 21,318 | 24,980 | 31,960 | 37,543 | 43,866 | 47,887 |
| R&D | (5,991) | (9,736) | (9,762) | (10,935) | (13,583) | (15,047) |
| SG&A | (11,294) | (15,234) | (18,419) | (19,216) | (19,977) | (19,851) |
| Adj. EBITDA | 8,680 | 11,506 | 14,507 | 15,641 | 18,208 | 19,927 |
| Total Debt | 19,699 | 29,794 | 28,279 | 27,494 | 28,843 | 30,874 |
| Gross Leverage | 2.3x | 2.6x | 1.9x | 1.8x | 1.6x | 1.5x |
| Interest Coverage | 11.8x | 16.0x | 17.1x | 14.5x | 13.9x | 15.2x |
CreditSight View Comment
AS OF 10 Feb 2026We reiterate our Outperform recommendation on AstraZeneca. AZN benefits from a deep portfolio of innovative medicines and one of the strongest growth trajectories in the space (trailing only Eli Lilly). We see AZN as attractive versus NVS (U/P), a name with a less compelling growth narrative and modestly higher net leverage (~1.4x pf).
Recommendation Reviewed: February 10, 2026
Recommendation Changed: April 01, 2021
Featured Issuers
Perusahaan Listrik Negara
Hyundai Motor
Republic of the Philippines
